Highlights

  • Vita Life Sciences (ASX:VLS) operates across vitamins, supplements and healthcare products, giving investors exposure to the consumer-health segment.
  • The Interim Dividend is $0.050 per share, with an annual Yield of 5.19%.
  • The shares are scheduled to trade ex-dividend on 18 September 2026, with the Record Date set for 21 September 2026.
  • The dividend is scheduled to be paid on 2 October 2026 and carries 60% franking.

Healthcare stocks are more often associated with growth than with income, which is part of what makes Vita Life Sciences (ASX:VLS) stand out. The vitamins, supplements and healthcare products group combines exposure to a defensive consumer-health niche with a Shareholder distribution profile that adds an income dimension to the Investment case.

Dividend Snapshot

Vita Life Sciences (ASX:VLS) has an interim dividend of $0.050 per share, with an annual yield of 5.19% based on the supplied dividend information.

As of 9 September 2026, the dividend remains upcoming. The shares are scheduled to trade ex-dividend on 18 September 2026, while the record date is set for 21 September 2026. Payment is scheduled for 2 October 2026.

The dividend carries 60% franking, meaning eligible Australian shareholders may receive franking credits on part of the payment. This can influence the after-tax value of the income stream depending on an investor’s individual tax circumstances.

What Is Supporting the Dividend?

Vita Life Sciences’ Earnings stem from the manufacture and sale of vitamins, supplements and health products across markets including Australia and parts of Asia. Consumer health is a relatively defensive category, with Demand for wellness and preventative products tending to be steadier than in more discretionary sectors.

That operating profile can support recurring cash generation, although the balance between reinvestment and shareholder distributions remains dependent on underlying profitability and Business requirements.

Expansion of the company’s healthcare footprint and product range may support future earnings, though the pace of growth and the amount of Capital required will influence how much cash remains available for distributions.

What Income Investors Should Watch

As a smaller healthcare company with international exposure, Vita Life Sciences (ASX:VLS) carries several risks worth monitoring. Currency movements, regulatory requirements across different health-product markets and changes in consumer demand can all affect earnings.

Competition in the vitamins, supplements and wellness market can also pressure margins, particularly if companies need to invest more heavily in branding, distribution or product development.

Liquidity can be another consideration for smaller listed companies. Income investors may additionally watch the company’s future franking capacity, particularly because the supplied interim dividend carries 60% franking rather than being fully franked.

Outlook

Vita Life Sciences (ASX:VLS) combines consumer-health exposure with an income profile that differentiates it from many growth-oriented healthcare names.

Its $0.050 per share interim dividend, carrying an annual yield of 5.19%, is scheduled to trade ex-dividend on 18 September 2026, with payment expected on 2 October 2026. The dividend carries 60% franking.

Looking ahead, earnings performance, product demand, currency movements, regulatory conditions and franking capacity are likely to remain important factors influencing the sustainability of future shareholder distributions.